AMGEN BIOSIMILARS

EUIPO EUIPO 2015 Trademark registered

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The Union trademark AMGEN BIOSIMILARS was filed as Figurative mark on 09/14/2015 at the European Union Intellectual Property Office.
It was registered as a trademark on 05/02/2016. The current status of the mark is "Trademark registered".

Logodesign (Wiener Klassifikation)

#Other parts of the human body, DNA band, cells, brains, sperms, hair roots (also 2.9.12) #Two lines or bands #Thick lines, bands #Wavy lines or bands, zigzag lines or bands

Trademark Details Last update: February 9, 2024

Trademark form Figurative mark
File reference 014556237
Application date September 14, 2015
Publication date January 22, 2016
Entry date May 2, 2016
Expiration date September 14, 2025

Trademark owner

One Amgen Center Drive
91320-1799 Thousand Oaks,
US

Trademark representatives

2Amsterdam Eduard van Beinumstraat 10 3rd Floor 1077 CZ Amsterdam NL

goods and services

5 Pharmaceutical preparations; pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders; pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis; pharmaceutical preparations and substances used for the treatment of polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis; pharmaceutical preparations and substances used for the treatment of systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis; pharmaceutical preparations and substances used for the treatment of palmoplantar psoriasis, hidradenitis suppurativa, pharmaceutical preparations and substances used for the treatment of bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders; pharmaceutical preparations and substances used for the treatment of age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer; pharmaceutical preparations and substances used for the treatment of glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis; pharmaceutical preparations and substances used for the treatment of graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression
41 Providing online publications in the nature of brochures and newsletters in the fields of pharmaceuticals, biosimilars, medicines and health; arranging and conducting classes, seminars and workshops in the fields of pharmaceuticals, biosimilars, medicines and health; educational services, namely, programs about pharmaceuticals, biosimilars, medicines and health accessible by means of audio, video, web-based applications, mobile phone applications, and computer networks; educational services, namely, conducting programs in the fields of pharmaceuticals, biosimilars, medicines and health
42 Research and development of pharmaceutical preparations and biosimilars; research and development in the pharmaceutical and biotechnology fields; medical and scientific research information in the fields of pharmaceutical preparations, biosimilars and clinical trials; pharmaceutical and biosimilar support services, namely, help desk services; providing online computer software used to access, manage, update and display electronic databases in the fields of pharmaceutical preparations and biosimilars
44 Providing websites featuring information about pharmaceutical preparations and biosimilars

Trademark history

Date Document number Area Entry
November 6, 2023 Change Representative, Published

ID: 11014556237